肿瘤细胞治疗研究
英文原题：Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma.
Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma.
复发或难治性 T 细胞急性淋巴细胞白血病/淋巴瘤（r/r T-ALL/LBL）常具有侵袭性，且与不良预后相关。
复发或难治性T细胞急性淋巴细胞白血病/淋巴瘤（r/r T-ALL/LBL）常具有侵袭性，预后不良。泛靶向嵌合抗原受体（CAR）T细胞疗法在临床试验中显示出良好前景。近年来，CD7 CAR-T和CD5 CAR-T治疗伴骨髓浸润的r/r T-ALL/LBL患者显示疗效。然而，近半数r/r T-ALL/T-LBL患者伴有髓外病变（EMD），而CAR-T疗法对此类患者的疗效和安全性数据仍有限。此外，CD7 CAR-T和CD5 CAR-T可能导致严重免疫缺陷及血液学毒性，并造成免疫重建困难。本综述深入分析CAR-T治疗r/r T-ALL/LBL的安全性特征和不良事件，尤其关注其对伴EMD患者的影响。
Relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/LBL) are frequently aggressive and associated with unfavorable prognoses. Pan-targeted Chimeric Antigen Receptor (CAR) T-cell therapy have shown promising results in clinical trials. In recent years, CD7 CAR T-cell and CD5 CAR T-cell demonstrate effectiveness in treating r/r T-ALL/LBL patients with bone marrow infiltration. However, nearly half of r/r T-ALL/T-LBL patients are accompanied by extramedullary disease (EMD), where comprehensive data on the efficacy and safety of CAR T-cell therapy remain limited. Additionally, CD7 CAR T-cell and CD5 CAR T-cell therapy can cause severe immunodeficiency and hematologic toxicity, complicating with difficult immune reconstitution. This review provides an in-depth analysis of the safety profile and adverse events associated with CAR T-cell therapy in r/r T-ALL/LBL, with a a particular emphasis on its impact in patients with EMD.
MEMBER ACCOUNT
登录成功会直接打开下一页。
